GURUFOCUS.COM » STOCK LIST » Industrials » Transportation » Kinarus Therapeutics Holding AG (XSWX:KNRS) » Definitions » Piotroski F-Score

Kinarus Therapeutics Holding AG (XSWX:KNRS) Piotroski F-Score : 0 (As of May. 26, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Kinarus Therapeutics Holding AG Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Kinarus Therapeutics Holding AG has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Kinarus Therapeutics Holding AG's Piotroski F-Score or its related term are showing as below:


Kinarus Therapeutics Holding AG Piotroski F-Score Historical Data

The historical data trend for Kinarus Therapeutics Holding AG's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kinarus Therapeutics Holding AG Piotroski F-Score Chart

Kinarus Therapeutics Holding AG Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 2.00 3.00 5.00 2.00

Kinarus Therapeutics Holding AG Semi-Annual Data
Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 - 5.00 - 2.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec21) TTM:Last Year (Dec20) TTM:
Net Income was CHF-0.14 Mil.
Cash Flow from Operations was CHF-0.36 Mil.
Revenue was CHF0.00 Mil.
Gross Profit was CHF0.00 Mil.
Average Total Assets from the begining of this year (Dec20)
to the end of this year (Dec21) was (0.127 + 0.136) / 2 = CHF0.1315 Mil.
Total Assets at the begining of this year (Dec20) was CHF0.13 Mil.
Long-Term Debt & Capital Lease Obligation was CHF0.43 Mil.
Total Current Assets was CHF0.14 Mil.
Total Current Liabilities was CHF0.11 Mil.
Net Income was CHF-0.01 Mil.

Revenue was CHF4.11 Mil.
Gross Profit was CHF0.17 Mil.
Average Total Assets from the begining of last year (Dec19)
to the end of last year (Dec20) was (2.174 + 0.127) / 2 = CHF1.1505 Mil.
Total Assets at the begining of last year (Dec19) was CHF2.17 Mil.
Long-Term Debt & Capital Lease Obligation was CHF0.28 Mil.
Total Current Assets was CHF0.13 Mil.
Total Current Liabilities was CHF0.10 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Kinarus Therapeutics Holding AG's current Net Income (TTM) was -0.14. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Kinarus Therapeutics Holding AG's current Cash Flow from Operations (TTM) was -0.36. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec20)
=-0.143/0.127
=-1.12598425

ROA (Last Year)=Net Income/Total Assets (Dec19)
=-0.007/2.174
=-0.00321987

Kinarus Therapeutics Holding AG's return on assets of this year was -1.12598425. Kinarus Therapeutics Holding AG's return on assets of last year was -0.00321987. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Kinarus Therapeutics Holding AG's current Net Income (TTM) was -0.14. Kinarus Therapeutics Holding AG's current Cash Flow from Operations (TTM) was -0.36. ==> -0.36 <= -0.14 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec20 to Dec21
=0.429/0.1315
=3.26235741

Gearing (Last Year: Dec20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec19 to Dec20
=0.28/1.1505
=0.24337245

Kinarus Therapeutics Holding AG's gearing of this year was 3.26235741. Kinarus Therapeutics Holding AG's gearing of last year was 0.24337245. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec21)=Total Current Assets/Total Current Liabilities
=0.136/0.107
=1.27102804

Current Ratio (Last Year: Dec20)=Total Current Assets/Total Current Liabilities
=0.127/0.104
=1.22115385

Kinarus Therapeutics Holding AG's current ratio of this year was 1.27102804. Kinarus Therapeutics Holding AG's current ratio of last year was 1.22115385. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Kinarus Therapeutics Holding AG's number of shares in issue this year was 163.768. Kinarus Therapeutics Holding AG's number of shares in issue last year was 168.434. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.172/4.109
=0.04185933

Kinarus Therapeutics Holding AG's gross margin of this year was . Kinarus Therapeutics Holding AG's gross margin of last year was 0.04185933. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec20)
=0/0.127
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec19)
=4.109/2.174
=1.8900644

Kinarus Therapeutics Holding AG's asset turnover of this year was 0. Kinarus Therapeutics Holding AG's asset turnover of last year was 1.8900644. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+0+1+1+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Kinarus Therapeutics Holding AG has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Kinarus Therapeutics Holding AG  (XSWX:KNRS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Kinarus Therapeutics Holding AG Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Kinarus Therapeutics Holding AG's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Kinarus Therapeutics Holding AG (XSWX:KNRS) Business Description

Traded in Other Exchanges
N/A
Address
3, Avenue de Florimont, Lausanne, CHE, CH-1006
Perfect Holding SA is a Switzerland-based company that focuses on the acquisition and management of investments in companies, which are active in the aircraft management and related services sector. The company operates in one business segment which includes Charters. The products provided by the company include Aircraft sales, Charter sales, and Aircraft consultancy.

Kinarus Therapeutics Holding AG (XSWX:KNRS) Headlines

No Headlines